Pharmacy Council of India Urged to Ban Forced Swim Test in Institutions
PETA India argues that the forced swim test is scientifically invalid: The test’s validity in accurately modeling human depression has been widely questioned by scientists. The test is also unduly cruel and causes significant distress and suffering to the animals involved.
Online Application Portal Launched for Extension of Revised Schedule M Compliance Deadline
The Central Drugs Standard Control Organization (CDSCO) has announced the launch of an online system for pharmaceutical manufacturers to apply for an extension of the timeline to comply with the revised Schedule M of the Drugs Rules, 1945. Pharmaceutical manufacturers who meet the criteria for seeking an extension of the revised Schedule M implementation timeline are encouraged to utilize the online application portal on the ONDLS website by May 11, 2025. This online platform is the only accepted method for submitting such applications.
India Strengthens Pharmaceutical Quality Control Amidst Growing Export Market
India, ranking 11th globally in pharmaceutical exports by value in 2023, is taking significant strides to enhance the quality, safety, and efficacy of its medicines. This comes as a 2025 Bain & Company report reveals India accounts for 3% of total global pharmaceutical exports.
NPPA Fixes Retail Price for Cilnidipine & Telmisartan Tablets
Each film coated Cilnidipine & Telmisartan Tablet shall bear the retail price of Rs. 14.15. This price applies to tablets manufactured by M/s Akums Drugs & Pharmaceuticals Ltd. and marketed by M/s Glenmark Pharmaceuticals Limited.
NPPA Revises Ceiling Prices of Azithromycin & Amoxicillin + Clavulanic Acid
Manufacturers selling these formulations (branded or generic) above the revised ceiling price (plus applicable GST) must immediately revise their prices downwards to comply. Retailers and dealers must prominently display the price list provided by the manufacturer.
NPPA Fixes Retail Prices For 42 Formulations
The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices for 42 pharmaceutical formulations. These prices are exclusive of Goods and Services Tax, if applicable. These prices were notified on February 7, 2025.
Government Issues Uniform Code to Regulate Pharmaceutical Marketing Practices
The Department of Pharmaceuticals has released the Uniform Code of Pharmaceutical Marketing Practices 2024, effective March 12, 2024, to curb unethical marketing and promote responsible pharmaceutical product promotion. The code focuses on regulating interactions between doctors/registered medical practitioners (RMPs) and pharmaceutical company representatives.
Draft Guidelines For The Pharmaceutical Industry In India
The Central Pollution Control Board (CPCB) has issued draft guidelines for the pharmaceutical industry aiming to regulate and mitigate its environmental impact. Stakeholders and the general public have until February 5, 2025, to provide their feedback on the proposed guidelines. Suggestions can be submitted via email to designated CPCB officials or sent to the IPC-I Division of CPCB in Delhi.
India’s Pharmaceutical Industry With Ambitious Growth Plans
India’s pharmaceutical industry is a significant force in the global market, boasting a strong domestic presence and a rapidly growing export sector. National Institutes of Pharmaceutical Education & Research (NIPERs) spearhead research efforts.
Government Ramps Up Production of Pharmaceuticals and Medical Devices in India
The PLI scheme for Bulk Drugs, with a financial outlay of Rs. 6,940 crore, incentivizes the manufacturing of essential Key Starting Materials (KSMs), Drug Intermediates (DIs), and Active Pharmaceutical Ingredients (APIs). With a budget of Rs. 15,000 crore, the PLI Scheme for Pharmaceuticals focuses on high-value products like patented/off-patented drugs, biopharmaceuticals, complex generics, and anti-cancer drugs. The PLI Scheme for Promoting Domestic Manufacturing of Medical Devices targets high-end medical devices previously imported into India.
